Something quiet but profound is happening in laboratories right now, and most people have no idea it’s real. Scientists aren’t just studying the brain anymore. They’re growing tiny pieces of it in a lab dish and wiring them into computers. Not simulating neural activity in software. Not modeling it with algorithms. Actually using living human brain tissue to perform computations. If that sentence made you stop and reread it, good. Because this field, called brain organoid biocomputers, is no longer a theoretical concept. It’s commercial, it’s cloud-accessible, and it’s accelerating in ways that are making both researchers and ethicists pay close attention.
The path here started years ago with a deceptively simple question: if silicon chips mimic the brain, why not just use the brain? Silicon is reaching its physical limits, and training today’s artificial intelligence systems devours electricity at a rate that has energy experts genuinely worried. Meanwhile, the human brain runs on roughly 20 watts, less power than a dim light bulb, while outperforming any AI system at learning, adaptation, and pattern recognition. That gap is what’s driving some of the most unusual science being done right now.
Understanding what’s being built, how it works, and what questions it raises takes a bit of unpacking. But it’s worth it. Because whether or not this technology lives up to its early promise, the fact that it exists at all says something significant about where biology and computing are headed.
What Brain Organoids Actually Are
Before getting into the computers themselves, it helps to understand the building block. Brain organoids are three-dimensional clusters of neural tissue grown in a lab from stem cells. More precisely, the neurons originate from induced pluripotent stem cells, known as iPSCs, which are capable of developing into virtually any cell type in the body. Scientists coax these stem cells into becoming neurons, which then self-organize into small spherical structures that resemble early-stage human brain tissue.
These miniature clusters are typically the size of a pea or smaller and contain various types of brain cells organized in a structure that mimics aspects of a developing human brain. While they don’t have the full complexity of an adult brain, organoids can develop basic neural circuits and exhibit spontaneous electrical activity. That spontaneous activity is important. It means the tissue is doing what neurons do: communicating.
What makes them useful for computing is the same thing that makes the brain useful for thinking. Neurons seek patterns. They form connections, strengthen the ones that work, and prune the ones that don’t. Neurons habitually search for patterns, seeking order and predictability, and you can create a virtual environment for them, complete with the capability to perform actions and perceive the results, using nothing but electrical stimulation.
How Brain Organoid Biocomputers Are Built
To turn an organoid into a computing device, researchers place it on a multi-electrode array, or MEA. In the Brainoware approach, computation is performed by sending and receiving information from the brain organoid using a high-density multielectrode array. Two-way electrodes can send pulses of electricity into the brain organoids and also measure the responses coming out of them.
The electrodes are the interface. Information goes in as electrical pulses, the neurons respond by firing and adjusting their connections, and the output is read back as electrical data. Brett Kagan is Chief Scientific Officer at Cortical Labs, a company building the world’s first commercial biological computer that fuses lab-cultivated neurons from human stem cells with hard silicon. As Kagan explained to Infinite Frontiers, “Using synthetic biological methods, we can generate neurons at scale and interact with them through electricity, which is the shared language of brains and silicon.”
Training organoids to produce useful responses is where things get genuinely creative. FinalSpark is a company co-founded by software engineer Dr. Fred Jordan, where researchers are creating what they call “wetware,” a new kind of computer made from living neurons. In an interview with Techopedia, Dr. Jordan explained their dopamine reward method: “We release dopamine precisely at the right time directly to the brain organoid by using a process called uncaging. We encapsulate dopamine in a molecular cage, invisible to the organoid initially. When we want to ‘reward’ the organoid, we expose it to specific light frequencies. This light opens the cage, releasing the dopamine and providing the intended stimulus to the organoid.” The organoids live in a microfluidic incubator kept at 37 degrees Celsius, essentially body temperature. This is a form of reinforcement learning, the same basic principle used in AI training, except applied to living cells instead of software.
The Companies Bringing This to Market
Two organizations have moved brain organoid biocomputers out of the research phase and into commercial products, and their approaches differ in interesting ways.
Cortical Labs began selling its bioprocessing units for $35,000 each, with units that house all the support systems – from waste filtration to temperature control – needed to keep human brain cells alive for up to six months. The shoebox-sized CL1 system is described as the world’s first code-deployable biological computer and could find applications in disease modeling and drug discovery. Around 200,000 living human neurons on a microchip power the device. Inside the CL1, a nutrient-rich broth feeds human neurons, which grow across a silicon chip. That chip sends electrical impulses to and from the neurons to train them to exhibit desired behaviors.
Cortical Labs offers three routes in. Scientists can buy the CL1 hardware and do everything themselves. They can access it via the cloud and interact with the cells remotely. Or Cortical Labs will run the whole experiment for them.
The early demonstrations have been deliberately attention-grabbing. Cortical Labs made headlines in 2022 when its scientists trained one of these brain organoids to play Pong, encoding the game’s variables, like ball and paddle positions, as patterns of electrical signals. More recently, a graduate student took the company’s CL1 hardware platform and, within roughly a week, got it running Doom. These aren’t claims of consciousness or human-level intelligence. They’re proofs of concept showing that living neurons can respond to structured input and produce consistent, adaptive outputs.
The Swiss company FinalSpark has taken a different approach, building a shared cloud platform instead of a standalone product. FinalSpark became, in 2023, the first biocomputing lab to offer remote access to its hardware, with nine universities receiving free accounts. Their interface, called Neuroplatform, allows researchers to write Python code and use an API to stimulate the neurons and listen to them. The company has since connected Neuroplatform to a large language model that can autonomously design and run experiments.
The Neuroplatform comprises 16 brain organoids arranged in four multi-electrode arrays, with each organoid containing approximately 10,000 neurons, yielding roughly 160,000 neurons system-wide. For anyone curious about the wider world of biological computing, how living human neurons power computers offers useful context on what these systems look like in practice.
The Energy Case for Living Computers
The practical argument for biocomputing comes down to energy, and the numbers are stark. Biological networks are better at handling chaotic, noisy data, and analyses of brain tissue suggest the biological brain runs on roughly 30 watts, which is less than some lightbulbs – while training a frontier AI model costs orders of magnitude more.
The contrast matters because AI energy demand is not slowing down. Training today’s largest models consumes electricity on par with entire towns. A rack of CL1 units consumes 850 to 1,000 watts, which is notably lower than the tens of kilowatts required by a data center setup running AI workloads.
Whether biocomputing can scale to a point where it genuinely dents that energy problem is still an open question. But the directional argument is sound. Biology figured out efficient computation billions of years before silicon did.
What Organoids Are Already Doing
Beyond Pong and Doom, researchers have put organoid biocomputers to more rigorous scientific tests. As detailed in a study published in Nature Electronics, a team at Indiana University successfully grew a nanoscale brain organoid in a Petri dish using human stem cells. After connecting the organoid to a silicon chip, the new biocomputer, dubbed Brainoware, was quickly trained to accurately recognize speech patterns, as well as perform certain complex math predictions. To test Brainoware’s capabilities, the team converted 240 audio clips of adult male Japanese speakers into electrical signals and sent them to the organoid chip. Within two days, the neural network system could accurately differentiate between the eight speakers 78% of the time using just a single vowel sound.
The same broad approach, wiring organoids to electrode arrays and providing structured training, is being explored for drug testing. The CL1 is described as enabling medical and research labs to test how real neurons process information, offering what the company calls an ethically superior alternative to animal testing while delivering more relevant human data.
That claim about relevance matters scientifically. Animal models don’t always predict how human biology responds to drugs. Human organoids, grown from human cells, are inherently more representative of human outcomes. Both Cortical Labs and FinalSpark expect customers well beyond the pharmaceutical industry, including AI researchers looking for new kinds of computing system.
On the regulatory side, on April 10, 2025, the FDA announced that it would begin phasing out mandatory animal testing requirements for certain new drug applications, starting with monoclonal antibody therapies, encouraging developers to use “human-relevant” methods including AI-driven models, organoids, and organ-on-a-chip systems to assess the safety and efficacy of their products. That institutional shift could meaningfully accelerate demand for organoid-based technology in the years ahead.
The Honest Limitations
Human brain cell-based biocomputers can perform simple tasks like playing Pong or basic speech recognition, but their neural activity remains primitive and far from consciousness. That’s an important distinction. Researchers in this field are careful to separate early functional capability from any suggestion of sentience or high-level intelligence.
Biocomputing is still in the early experimental stage, and there are significant limitations. Human brains contain about 86 billion neurons. Current organoids max out at thousands to millions, impressive for a lab dish, but still orders of magnitude away from matching brain-level complexity. Scaling them up without losing stability or function is one of the hardest scientific challenges.
Lifespan is another constraint. Organoid lifespan is reported at approximately 100 days under operating conditions, up from hours in early experiments. Cortical Labs reports their CL1 system can maintain neurons for up to six months with the right support infrastructure, though that represents an upper bound under carefully managed conditions.
The most fundamental challenge is unpredictability. Unlike silicon chips, which can be manufactured with near-perfect consistency, living systems are not. No two organoids behave the same way, and keeping them alive for extended periods remains a challenge. This is not a solvable-with-better-software problem. It’s a biological reality that the field is still working around.
The Ethics That Come With It
The moral questions surrounding brain organoid biocomputers are real, and serious researchers are not dismissing them. Thomas Hartung at Johns Hopkins University was among the first to formally articulate the concept of “organoid intelligence” in a 2023 paper in Frontiers in Science, framing the combination of brain organoids and AI as a new frontier in biological computing and calling explicitly for ethical frameworks to develop alongside the science.
The central concern is whether organoids could develop some form of experience or consciousness. Current organoids are orders of magnitude less complex than a human brain, and researchers are careful to point out that no established scientific method exists for determining whether a neural network realizes consciousness. That uncertainty cuts both ways. It means we can’t confirm organoids are conscious, but we also can’t rule it out as they become more complex.
Other concerns center on donor consent. The human cells used to grow organoids come from real people. Whether those people understood their tissue might end up in a commercial computing product is a question worth asking. The questions on the table are familiar from stem cell research: the moral status of organoids, the possibility of something like consciousness in sufficiently complex systems, informed consent from the donors whose cells were reprogrammed, and thorny questions about commercialization and intellectual property.
Cortical Labs and FinalSpark are both working with bioethicists, but the field is moving fast enough that the ethical frameworks are somewhat playing catch-up. Cortical Labs has tried to get ahead of this by publishing an ethics paper as one of its first formal academic outputs and working with independent bioethicists on questions of moral status and governance. The company also emphasizes that the CL1 is entirely free of animal testing, positioning it as an ethical alternative that delivers more relevant human data.
What This Means for You
Brain organoid biocomputers are unlikely to change your life next year. But they are likely to change medicine, computing, and drug development within a decade in ways that will affect you indirectly. If organoid-based testing replaces animal models in pharmaceutical research, the drugs that reach clinical trials should be more relevant to human biology, which means better predictions of side effects and efficacy before a treatment ever reaches a patient. That’s not a minor improvement. It’s the kind of shift that could reduce the number of drugs that fail late in development after years of cost and patient risk.
The energy dimension matters too. If AI continues expanding at its current rate and organoid-based systems prove they can run meaningful computations at a fraction of the power cost, biocomputing could eventually become part of the infrastructure that makes sustainable AI possible. That’s a long road from 200,000 neurons playing Doom, but the direction of travel is clear.
For now, the most useful thing to understand is that this technology exists, it’s commercially available, it works at a basic level, and the people building it are actively engaging with the ethical questions it raises. The science is young. The limitations are real. But so is the momentum. Keeping an eye on this field – and thinking critically about what it means for human tissue, consent, and computation – is no longer optional for anyone paying attention to where biology and technology are converging.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Supercomputer Predicts The Year of Human Extinction